Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan dose-exploration trial in active lupus nephritis
2023-509332-26-00Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial of Iptacopan in lupus nephritis (LN) (4 arms), sponsored by Novartis. Primary endpoint: Complete Renal Response at week 24. Started Feb 2023; status: completed.
02
Drugs
Iptacopan
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on 2023-509332-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509332-26-00.